Brain Tumours

Phase 1 study of dabrafenib in pediatric patients with relapsed or refractory BRAFV600-mutant high-grade gliomas, low-grade gliomas, histiocytosis, and other solid tumors Mark W Kieran 1 , Darren Hargrave 2 , Ken Cohen 3 , Isabelle Aerts 4 , Ira J Dunkel 5 , Trent R Hummel 6 , Irene Jimenez 4 , Andrew Pearson 7 , Christine Pratilas 3 , James Whitlock 8 , Eric Bouffet 8 , Violet Shen 9 , Alberto Broniscer 10 , Anne-Isabelle Bertozzi 11 , Joan Sandberg 12 *, Allison Florance 12 *, Benjamin Suttle 12 § , Patricia Haney 12† , Mark Russo 12 *, Birgit Geoerger 13

1 Dana-Farber Cancer Institute and Boston Children ’ s Hospital, Boston, MA, USA; 2 Great Ormond Street Hospital for Children, London, UK; 3 Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4 Curie Institute, Paris France; 5 Memorial Sloan Kettering Cancer, New York, NY, USA; 6 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 7 The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK; 8 Hospital for Sick Children, Toronto, Ontario, Canada; 9 Children's Hospital of Orange County, Orange, CA, USA; 10 St. Jude Children's Research Hospital, Memphis, TN, USA; 11 CHU de Toulouse - Hôpital des Enfants,

Toulouse, France; 12 GlaxoSmithKline, RTP, NC, USA; 13 Gustave Roussy, Villejuif, France * Current affiliation : Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; § Current affiliation : Salix Pharmaceuticals, Raleigh, NC, USA; † Current affiliation : Pfizer Inc, New York, NY, USA